Bourguillon Richard O, Stokes William A, Dorth Jennifer, Schmitt Nicole C
Morehouse School of Medicine, Atlanta, Georgia, USA.
Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
OTO Open. 2021 Dec 11;5(4):2473974X211065715. doi: 10.1177/2473974X211065715. eCollection 2021 Oct-Dec.
The rising incidence of head and neck squamous cell carcinoma (HNSCC) calls for the assessment and improvement of currently available therapies that may enhance the therapeutic ratio in these patients. Statin drugs are one of the most widely used drug classes in the world for their lipid-lowering properties. As such, statins have been widely studied and found to possess pleiotropic effects that may make them effective in cancer treatment and toxicity mitigation. The aim of this review is to examine the potential use of statin drugs as adjunctive therapy in patients with HNSCC.
PubMed.
Any preclinical or clinical articles pertaining to the effects of statin drugs on treatment-related toxicity or survival outcomes in patients with head and neck cancer were included in this narrative review.
Emerging data suggest that statins may improve survival and reduce toxicities associated with chemotherapy and radiotherapy in patients with head and neck cancer, by mechanisms that are poorly understood at present.
Given their affordability and safety, statins deserve further study as a tool to improve oncologic outcomes and enhance survivorship in patients with HNSCC.
头颈部鳞状细胞癌(HNSCC)发病率不断上升,需要对目前可用的治疗方法进行评估和改进,以提高这些患者的治疗效果。他汀类药物因其降脂特性而成为世界上使用最广泛的药物类别之一。因此,他汀类药物已得到广泛研究,并发现具有多效性作用,这可能使其在癌症治疗和毒性缓解方面有效。本综述的目的是探讨他汀类药物作为HNSCC患者辅助治疗的潜在用途。
PubMed。
本叙述性综述纳入了任何关于他汀类药物对头颈部癌患者治疗相关毒性或生存结果影响的临床前或临床文章。
新出现的数据表明,他汀类药物可能通过目前尚不清楚的机制,改善头颈部癌患者的生存率,并降低与化疗和放疗相关的毒性。
鉴于他汀类药物的可负担性和安全性,值得进一步研究将其作为改善HNSCC患者肿瘤学结局和提高生存率的工具。